share_log

HC Wainwright & Co. Maintains Buy on Aadi Bioscience, Lowers Price Target to $45

HC Wainwright & Co. Maintains Buy on Aadi Bioscience, Lowers Price Target to $45

HC Wainwright & Co.维持对Aadi Bioscience的买入,将目标价下调至45美元
Benzinga ·  2023/03/29 06:13

HC Wainwright & Co. analyst Robert Burns maintains Aadi Bioscience (NASDAQ:AADI) with a Buy and lowers the price target from $48 to $45.

HC Wainwright&Co.分析师罗伯特·伯恩斯坚持认为Aadi Bioscience(纳斯达克:AADI)为买入,并将目标价从48美元下调至45美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发